Cite
Effects of a pro-resolving drug in COVID-19: preclinical studies to a randomized, placebo-controlled, phase Ib/IIa trial in hospitalized patients.
MLA
Almeida, Pedro R. J., et al. “Effects of a Pro-Resolving Drug in COVID-19: Preclinical Studies to a Randomized, Placebo-Controlled, Phase Ib/IIa Trial in Hospitalized Patients.” British Journal of Pharmacology, Aug. 2024. EBSCOhost, https://doi.org/10.1111/bph.17322.
APA
Almeida, P. R. J., Periard, A. M., Tana, F. L., Avila, R. E., Milhorato, L. B., Alcantara, K. M. M., Resende, C. B., Serufo, A. V., Santos, F. R., Teixeira, D. C., Queiroz-Junior, C. M., Fonseca, T. C. M., Silva, B. L. V., Costa, V. V., Souza, R. P., Perretti, M., Jonassen, T. E. N., & Teixeira, M. M. (2024). Effects of a pro-resolving drug in COVID-19: preclinical studies to a randomized, placebo-controlled, phase Ib/IIa trial in hospitalized patients. British Journal of Pharmacology. https://doi.org/10.1111/bph.17322
Chicago
Almeida, Pedro R J, Alexandre M Periard, Fernanda L Tana, Renata E Avila, Larissa B Milhorato, Katlen M M Alcantara, Carolina B Resende, et al. 2024. “Effects of a Pro-Resolving Drug in COVID-19: Preclinical Studies to a Randomized, Placebo-Controlled, Phase Ib/IIa Trial in Hospitalized Patients.” British Journal of Pharmacology, August. doi:10.1111/bph.17322.